INSIGHTS ON DRUG DEVELOPMENT

• The Body As A Bioreactor – Delivering The Vision

  Making the body a bioreactor requires precise delivery to selected cells. See how lipid nanoparticles, manufacturing science, and biology are converging to overcome biological barriers and improve the targeting of advanced therapies.

• Silyl Ether Linkers For Hydroxyl-Bearing Payload Conjugates

  Discover an innovative approach to drug conjugation that expands the range of molecules suitable for targeted therapies while preserving their biological activity and enabling controlled drug release.

• Drug Development Plan Explained: DPP Templates And Examples

  Only 6.7% of Phase 1 drugs reach approval. A well-structured Drug Development Plan (DDP) can meaningfully improve your odds — learn exactly how to build one.

• Accelerating Small Molecule Protein Degrader Development Using High-Content Imaging

  High‑content imaging enables rapid discovery and optimization of small‑molecule protein degraders by delivering multiparametric, single‑cell insights that accelerate hit identification, SAR development, and lead advancement.

• Take Action On PFAS To Protect Your Critical Processes

  9/18/2025

  PFAS restrictions are tightening, but a full ban could disrupt critical industries lacking alternatives, such as pharmaceutical manufacturing. Learn where PFAS use remains indispensable.

• Cost Modeling Analysis Of AAV And LV Manufacturing

  3/31/2026

  Manufacturing scale plays a critical role in viral vector economics. Compare AAV and LV production scenarios to gain insight into how intermediate-scale strategies can reduce cost and risk.

• Accelerating Development With Rapid Delivery Of Toxicological Study Material

  3/19/2025

  Explore key strategies and technologies designed to address the analytical considerations and material flows to facilitate the rapid delivery of toxicological material.

• 3D Cell Culture Reveals Undetectable Drug Efficacy In Traditional Systems

  3/10/2025

  Drug discovery now targets cancer stem cells (CSCs) to achieve long-term tumor eradication, which moves beyond traditional chemotherapeutics. Discover an advanced screening platform that better predicts CSC inhibitor efficacy.

• How Biocatalysts Address Process Development Issues

  7/23/2026

  Antje Gupta, General Manager of Cambrex IEP in Wiesbaden, on where biocatalysis outperforms conventional chemistry — matching enzyme classes to target conversions and production volumes to find the more scalable, more economical route.